ACE inhibitor dry cough
ACE inhibitors (-pril) inhibit the conversion of angiotensin I to angiotensin II and concurrently slow the breakdown of bradykinin. Accumulated bradykinin causes a dry, persistent, tickling, non-productive cough in 5-20% of patients, more common in women and certain ethnic groups, and can occur weeks to months after initiation. The cough does not respond to OTC cough syrup, but resolves within 1-4 weeks of discontinuation. The standard management is provider notification and a switch to an angiotensin receptor blocker (ARB, -sartan) — losartan, valsartan, olmesartan — which provides the same RAAS blockade without bradykinin accumulation. The nurse must not advise self-discontinuation (rebound HTN risk) or downplay the symptom.
In-depth explanation
Why option 2 is correct
ACE inhibitors (-pril drugs) block conversion of angiotensin I to angiotensin II and also decrease bradykinin breakdown. Bradykinin accumulation can cause a dry, tickling, nonproductive cough in about 5-20% of clients, often weeks to months after initiation. OTC cough syrup usually does not help; the cough typically resolves 1-4 weeks after discontinuation. Standard management is to notify the prescriber and switch to an ARB (-sartan, such as losartan, valsartan, or olmesartan), which provides RAAS blockade without bradykinin buildup.
Distractor review
Option 1: ACE inhibitor cough does not reliably resolve within 48 hours and is not treated with OTC syrup alone. Option 3: self-discontinuation can cause rebound hypertension and cardiovascular risk. Option 4: the cough is an adverse effect, not a beneficial sign.
Cross-pharmacology point
After switching to an ARB, first-dose hypotension, hyperkalemia, and rare angioedema still require monitoring, but dry cough is much less common. New cough in a long-term ACE inhibitor user should still prompt assessment for other causes such as pneumonia or postnasal drip.
For study reference only. Always follow current clinical guidelines and your institution’s protocols.